{"id":3953,"date":"2023-09-19T14:36:56","date_gmt":"2023-09-19T12:36:56","guid":{"rendered":"https:\/\/www.antaresvisiongroup.com\/lifescience\/?p=3953"},"modified":"2023-09-22T17:28:51","modified_gmt":"2023-09-22T15:28:51","slug":"dscsa-compliance-nabp-partner-program","status":"publish","type":"post","link":"https:\/\/antaresvisiongroup.com\/lifescience\/2023\/09\/19\/dscsa-compliance-nabp-partner-program\/","title":{"rendered":"ANTARES VISION GROUP, THROUGH RFXCEL TECHNOLOGY, BECOMES THE FIRST DSCSA COMPLIANCE SOLUTION PROVIDER TO JOIN NABP\u2019S\u00ae INTEROPERABLE PARTNER PROGRAM"},"content":{"rendered":"\n<h2 class=\"wp-block-heading\">AV Group, which has a long history of working with the National Association of Boards of Pharmacy\u00ae, extends its commitment to DSCSA compliance by joining the Pulse Interoperable Partner Program<\/h2>\n\n\n\n<p>Antares Vision Group has joined <a href=\"https:\/\/nabp.pharmacy\/news\/news-releases\/nabp-launches-pulse-interoperable-partner-program-to-accelerate-interoperability-in-drug-supply-chain\/\" target=\"_blank\" rel=\"noreferrer noopener\"><strong>National Association of Boards of Pharmacy<sup>\u00ae<\/sup> (NABP<sup>\u00ae<\/sup>)<\/strong> <strong>Interoperable Partner Program<\/strong>.<\/a> This new initiative aims to <strong>accelerate interoperability in the drug supply chain<\/strong> and provide a framework for solution providers to integrate directly with Pulse by NABP<strong><sup>\u00ae<\/sup><\/strong>, an inclusive, accessible, and secure digital platform that simplifies the process of achieving <strong>Drug Supply Chain Security Act (DSCSA) compliance<\/strong>.<\/p>\n\n\n\n<p>Nearly 10 years ago, the Food and Drug Administration (FDA) established the DSCSA to ensure the safety of the U.S. pharmaceutical supply chain. The law requires cooperation and interoperability among a wide range of industry stakeholders and solution providers. As the deadline approaches, these actors must continue to work together to ensure they will meet the complex requirements of the DSCSA.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">How does the Interoperable Partner Program help in DSCSA compliance?<\/h2>\n\n\n\n<p>NABP<strong><sup>\u00ae<\/sup><\/strong> has been and will continue to be a key stakeholder in the DSCSA effort, representing the needs and interests of dispensers and distributors. <\/p>\n\n\n\n<p>This includes <strong><a href=\"https:\/\/nabp.pharmacy\/pulse\/\" target=\"_blank\" rel=\"noreferrer noopener\">Pulse by NABP<\/a><sup>\u00ae<\/sup><\/strong>, which <strong>facilitates DSCSA compliance across the supply chain by providing additional functionality and data required to ensure seamless interoperability among participants<\/strong>. Antares Vision Group, through rfxcel technology, recognizes the importance NABP\u2019s contributions and is proud to be the first solution provider to sign up for this partner program.<\/p>\n\n\n\n<p><em>\u201cWe have been working with the <a href=\"https:\/\/nabp.pharmacy\/\" target=\"_blank\" rel=\"noreferrer noopener\">NABP<strong><sup>\u00ae<\/sup><\/strong><\/a> for years and have watched their continued commitment to the DSCSA effort,\u201d<\/em> said rfxcel Senior Vice President of Product and Strategy Herb Wong. <em>\u201cTheir involvement offers critical insight into the needs of dispensers and other industry actors and reflects the feedback that we\u2019ve been hearing from our customers. <strong>We are excited to participate in the Interoperable Partner Program to ensure safe pharmaceuticals for patients and consumers.\u201d<\/strong><\/em><\/p>\n\n\n\n<p><em>\u201dAntares Vision Group became the first solution provider to be a Pulse Interoperable Partner, signing on within hours of the programme being announced at&nbsp; NABP\u2019s recent Interoperability Summit,\u201d<\/em> said NABP Executive Director\/Secretary Lemrey \u201cAl\u201d Carter, PharmD, MS, RPh. <em>\u201cThey have been an <strong>ardent supporter of Pulse and we\u2019re delighted to continue the collaboration to secure the prescription drug supply chain and protect public health.\u201d<\/strong><\/em><\/p>\n\n\n\n<p>Last 25 August, in a <a href=\"https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/enhanced-drug-distribution-security-requirements-under-section-582g1-federal-food-drug-and-cosmetic\" target=\"_blank\" rel=\"noreferrer noopener\">guidance document<\/a>, the FDA announced that it was delaying by one year enforcement of key requirements under the DSCSA. The DSCSA delay moves the enforcement date to November 27, 2024.<\/p>\n\n\n\n<p>The guidance is primarily for manufacturers, wholesale distributors, dispensers, and repackagers; delayed enforcement pertains to product identifiers at the package level; saleable returns; interoperable, electronic product tracing; and investigating suspect and illegitimate products.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>AV Group, which has a long history of working with the National Association of Boards&#8230;<\/p>\n","protected":false},"author":6,"featured_media":4041,"comment_status":"closed","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[14],"tags":[],"class_list":["post-3953","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"acf":[],"lang":"en","translations":{"en":3953,"it":4046},"pll_sync_post":[],"_links":{"self":[{"href":"https:\/\/antaresvisiongroup.com\/lifescience\/wp-json\/wp\/v2\/posts\/3953","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/antaresvisiongroup.com\/lifescience\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/antaresvisiongroup.com\/lifescience\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/antaresvisiongroup.com\/lifescience\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/antaresvisiongroup.com\/lifescience\/wp-json\/wp\/v2\/comments?post=3953"}],"version-history":[{"count":5,"href":"https:\/\/antaresvisiongroup.com\/lifescience\/wp-json\/wp\/v2\/posts\/3953\/revisions"}],"predecessor-version":[{"id":4050,"href":"https:\/\/antaresvisiongroup.com\/lifescience\/wp-json\/wp\/v2\/posts\/3953\/revisions\/4050"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/antaresvisiongroup.com\/lifescience\/wp-json\/wp\/v2\/media\/4041"}],"wp:attachment":[{"href":"https:\/\/antaresvisiongroup.com\/lifescience\/wp-json\/wp\/v2\/media?parent=3953"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/antaresvisiongroup.com\/lifescience\/wp-json\/wp\/v2\/categories?post=3953"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/antaresvisiongroup.com\/lifescience\/wp-json\/wp\/v2\/tags?post=3953"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}